The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature by Jacques Rizkallah et al.
Rizkallah et al. BMC Res Notes  (2016) 9:370 
DOI 10.1186/s13104-016-2116-1
CASE REPORT
The use of dronedarone for recurrent 
ventricular tachycardia: a case report and review 
of the literature
Jacques Rizkallah1, Vikas Kuriachan1 and L. Brent Mitchell1,2*
Abstract 
Background: Dronedarone is a benzofuran derivative resembling amiodarone that was intended to reduce the 
iodine-associated tissue deposition and organ toxicity seen with the latter. The utility of dronedarone for patients with 
ventricular arrhythmias has not been thoroughly evaluated. We present our experience with its use to treat refractory 
ventricular tachycardia storm and review the literature.
Case presentation: An 85 year-old gentleman with multiple medical comorbidities including ischemic and non-
ischemic cardiomyopathy with severe biventricular systolic dysfunction presented with ventricular tachycardia storm. 
Therapeutic options were limited given his frail medical status, failures of sotalol, mexilitine, and catheter ablation 
therapies along with drug-toxicities from amiodarone. Dronedarone was thus considered as off-label use following 
informed consent. The patient unfortunately developed fatal multisystem organ failure including acute severe hepa-
totoxicity from dronedarone.
Conclusion: Novel therapies for drug-refractory ventricular arrhythmias are long overdue given the limitations of 
available pharmacologic and non-pharmacologic options. Off-label use of antiarrhythmic agents such as dronedar-
one is considered a treatment of last-resort in patients who otherwise have no therapeutic options. Given the paucity 
of reported cases regarding dronedarone for the treatment of ventricular tachyarrhythmias, no conclusive recom-
mendations can be made at this time aside from words of caution. Despite the potential ventricular antiarrhythmic 
effects of dronedarone, careful patient evaluation is required to identify those at greatest risk of drug-related adverse 
events particularly in those patients with significant comorbidities such as advanced hepatic, renal, and cardiovascular 
disease.
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Background
Amiodarone is one the most effective pharmacologic 
agents to treat ventricular arrhythmias however its use is 
limited by a high incidence of drug-related adverse events 
[1]. Dronedarone is a benzofuran derivative resembling 
amiodarone with the iodine moiety replaced by a meth-
ane-sulfonyl group [2]. Its development was intended to 
reduce the iodine-associated tissue deposition and organ 
toxicity of amiodarone [2]. The utility of dronedarone for 
patients with ventricular arrhythmias has not been thor-
oughly evaluated [3]. We present our experience with its 
use in a patient with refractory ventricular tachycardia 
(VT) storm and review the literature to further guide its 
use in this setting.
Case presentation
An 85  year-old Caucasian gentleman with hyperten-
sion, paroxysmal atrial fibrillation, hypothyroidism, 
stage 3 chronic kidney disease, mixed ischemic and 
non-ischemic cardiomyopathy, severe biventricular sys-
tolic dysfunction, secondary prevention cardiac resyn-
chronization therapy device implant with defibrillator 
Open Access
BMC Research Notes
*Correspondence:  Brent.Mitchell@albertahealthservices.ca 
2 C829 Foothills Medical Centre, 1403 29 Street NW, Calgary, AB T2N 2T9, 
Canada
Full list of author information is available at the end of the article
Page 2 of 4Rizkallah et al. BMC Res Notes  (2016) 9:370 
function, and frequent monomorphic VT presents with 
VT storm. Heart failure medical therapy was optimized 
and included beta-blockade. A prior trial of sotalol ther-
apy provided no arrhythmia suppression. Amiodarone 
therapy provided some relief, particularly when aug-
mented by mexilitine therapy, however drug-related lung 
and neurologic toxicities limited amiodarone use. Trans-
venous catheter VT ablation was attempted however the 
arrhythmia recurred a month later.
On presentation, the patient had recurrent VT at 215 
beats per minute. 12-lead electrocardiography revealed a 
monomorphic wide complex tachycardia with left bun-
dle branch block like morphology, inferior axis, and late 
precordial transition. His arrhythmia precipitated fre-
quent appropriate implantable cardioverter defibrillator 
anti-tachycardia pacing and shocks therapies. There was 
no evidence of ongoing reversible myocardial ischemia or 
metabolic and electrolyte abnormalities.
Given his severe biventricular failure, prior sotalol 
and mexilitine failure, and drug-toxicities with ami-
odarone, antiarrhythmic options were limited. The 
patient was not a good candidate for a repeat ablation 
procedure or cardiac transplantation given his age and 
frail status. Having exhausted antiarrhythmic options, 
dronedarone therapy was considered for off-label use. 
After discussing potential benefits and risks regard-
ing dronedarone use in the treatment of VT based on 
the limited data available in the scientific literature, the 
patient consented to an off-label trial of the agent at 
400  mg twice daily. After only three doses, it was dis-
continued due to severe nausea and the development 
of multisystem organ failure including acute severe 
hepatotoxicity. This brief trial of dronedarone therapy 
had no appreciable effect of the patient’s VT burden. 
The duration of the VT episodes was brief and not felt 
to be the cause of the patient’s multi-organ failure that 
was temporally associated with the initiation of drone-
darone therapy. Five days prior to dronedarone admin-
istration, the patient’s serum alanine transaminase was 
measured at 59 U/L (normal 11–63 U/L), serum creati-
nine at 135 umol/L (normal 50–120 umol/L), and esti-
mated glomerular filtration rate at 41 mL/min/1.73 m2 
(normal >80 ml/min/1.73 m2). Two days after dronedar-
one administration a marked decline in kidney and liver 
function was observed with a serum alanine transami-
nase level increase to 1045 U/L, serum creatinine level 
of 231  umol/L, and estimate glomerular filtration rate 
of 21 ml/min/1.73 m2. Dronedarone therapy was subse-
quently discontinued. Unfortunately the patient’s liver 
and renal failure continued to worsen despite drug dis-
continuation. He died eight days later from multi-organ 
system failure and metabolic shock.
Discussion
Only three cases have been published thus far in the 
medical literature documenting the successful use of 
dronedarone for recurrent VT [4–6] and no cases have 
been published documenting its failure in this regard.
An 81 year-old male with non-ischemic cardiomyopa-
thy and severe left ventricular systolic dysfunction was 
receiving amiodarone and a beta-blocker in addition to 
optimized heart failure medical therapy but continued to 
have recurrent episodes of VT [4]. The use of amiodarone 
therapy was limited by thyroid toxicity requiring its dis-
continuation. Sotalol and propafenone were trialed and 
discontinued secondary to intolerance and procainamide 
therapy was unsuccessful. The patient declined VT cath-
eter ablation and dronedarone was subsequently offered 
as an option of last-resort with the clear understanding 
of its off-label use. In this patient, dronedarone therapy 
was associated with a significant reduction in arrhythmia 
burden.
The second case of successful dronedarone use for 
VT therapy in severe LV systolic dysfunction was in a 
42  year-old patient with “end-stage” hypertrophic car-
diomyopathy presenting with recurrent hemodynam-
ically-stable, monomorphic VT [5]. He was started on 
intravenous amiodarone that resulted in arrhythmia sup-
pression. Given the patient’s young age and concerns for 
long-term toxicity risks with amiodarone therapy, drone-
darone 400  mg twice daily was initiated and was well 
tolerated. The patient remained arrhythmia free after 
24 months of follow-up.
The third case of successful dronedarone use for the 
suppression of VT was in a 41 year old gentleman with 
non-ischemic dilated cardiomyopathy, mild LV systolic 
dysfunction, and frequent monomorphic non-sustained 
VT episodes [6]. The patient had delayed enhancement 
on cardiac MRI in the basal segment of the interventricu-
lar septum consistent with scar-based cardiomyopathy in 
the absence of coronary artery disease. He subsequently 
had an endocardial VT ablation attempt which was not 
successful and continued to have recurrent tachycardia 
despite trials of multiple antiarrhythmic agents including 
sotalol, propafenone, mexiletine, quinidine, amiodarone, 
and ranolazine. His amiodarone therapy was discontin-
ued due to concerns for long-term toxicities. Off-label 
dronedarone therapy was initiated and resulted in a sig-
nificant reduction in arrhythmia burden after a 3 months 
follow-up period.
In distinction to these cases, our patient did not toler-
ate dronedarone and died from severe drug-related hepa-
totoxicity and metabolic shock. Although its use for the 
treatment of VT is off-label, in this setting it was a treat-
ment of last resort.
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A review of the literature regarding dronedarone 
will assist in its appropriate clinical use. Dronedarone 
was well studied in atrial fibrillation (AF) and guidance 
regarding its use to treat ventricular arrhythmias can 
be extrapolated from these well-designed studies. The 
ATHENA-investigators randomized 4628 patients with 
paroxysmal or persistent AF or flutter who had no severe 
heart failure symptoms to dronedarone 400  mg twice 
daily or placebo but only an estimated 4  % of patients 
had severe LV systolic dysfunction [2]. In addition to a 
significant reduction in AF recurrence (hazard ratio of 
0.63), dronedarone reduced hospitalizations due to car-
diovascular events or death likely by reducing ventricular 
arrhythmias. Dronedarone has also been documented to 
have ventricular antiarrhythmic effects in animal mod-
els with ischemia-induced arrhythmias [7, 8]. The most 
significant clinical adverse events of dronedarone were 
bradycardia, QT-prolongation, nausea, diarrhea, abnor-
mal liver-function tests, and increased serum creatinine.
Dronedarone should be avoided or used with extreme 
caution in the setting of severe left ventricular dysfunc-
tion. In a randomized double-blind trial of 637 hospital-
ized patients with symptomatic heart failure and severe 
left ventricular dysfunction therapy with dronedarone 
400 mg twice daily increased early mortality secondary to 
progressive heart failure particularly in those with severe 
systolic dysfunction [9]. These observations suggest that 
dronedarone may directly or indirectly worsen left ven-
tricular systolic function. Patients treated with dronedar-
one were also noted to have a 10–20 % increase in serum 
creatinine that is considered to be due to inhibition of 
renal tubular cation secretion rather than a true change 
in glomerular filtration rate [10]. However, dronedarone 
therapy has been associated with an increased risk of 
acute renal failure based on published case reports and 
adverse drug-reaction databases [11, 12]. The mechanism 
of renal failure is unknown but may be mediated by its 
multichannel blocking activity [11]. Serum creatinine 
may increase by more than 10 % during the first week of 
dronedarone therapy, an observation that does not nec-
essarily herald impending renal failure. Nevertheless, 
progressive deterioration in kidney function based on 
laboratory measurements or clinical symptoms warrants 
discontinuation of dronedarone therapy and careful reas-
sessment of renal function [13].
Dronedarone should be avoided or used cautiously 
with underlying permanent AF. Its use in this particular 
subgroup was associated with increased heart failure, 
stroke, and death from cardiovascular causes in a rand-
omized trial of 3236 subjects [14]. The specific mecha-
nism of this adverse effect remains unclear.
Dronedarone-associated hepatotoxicity was suggested 
in as many as 12 % of study patients who had an elevation 
in liver enzymes [2, 15]. Since market release, three cases 
of severe hepatitis have been reported with two requiring 
urgent liver transplantation [16, 17]. These cases prompted 
the FDA to issue a warning about possible severe hepa-
totoxicity with dronedarone use. No dosage adjustment 
is required in patients with mild-to-moderate hepatic 
impairment; however, dronedarone therapy is contrain-
dicated in patients with severe hepatic dysfunction [13]. 
The mechanism of hepatic injury is likely similar to that 
of amiodarone and relates to drug-mediated inhibition of 
mitochondrial beta-oxidation and uncoupling of oxidative 
phosphorylation leading the cellular injury [17, 18].
Conclusion
Novel therapies for drug-refractory ventricular arrhyth-
mias are long overdue given the limitations of available 
pharmacologic and non-pharmacologic options. Off-
label use of antiarrhythmic agents such as dronedarone is 
considered a treatment of last-resort in patients who oth-
erwise have no therapeutic options. Given the paucity of 
reported cases regarding dronedarone for the treatment 
of ventricular tachyarrhythmias, no conclusive recom-
mendations can be made at this time other than advising 
caution. Despite its potential ventricular antiarrhythmic 
effects careful patient evaluation is required to iden-
tify those at greatest risk of drug-related adverse events 
particularly in those patients with significant comorbidi-
ties such as advanced hepatic, renal, and cardiovascular 
disease.
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